ONESOURCE vs ORCHPHARMA: Stock Comparison
ONESOURCE SPECL PHARMA L is the larger company by market capitalisation. ONESOURCE SPECL PHARMA L shows a lower P/E and faster revenue growth, while ORCHID PHARMA shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ONESOURCE leads 5; ORCHPHARMA leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ONESOURCE | ORCHPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ONESOURCE | ORCHPHARMA |
|---|---|---|
| Live Price | ₹1,592.2 | ₹1,003.05 |
| Day Change | 3.26% | -1.28% |
| Volume | 9.19 L | 68,916 |
| 52-Week High | ₹1,925 | ₹1,133 |
| 52-Week Low | ₹1,057 | ₹480 |
| Distance from 52W High | -17.29% | -11.47% |
Valuation
| Metric | ONESOURCE | ORCHPHARMA |
|---|---|---|
| Market Cap | ₹18,225 Cr | ₹5,123 Cr |
| P/E Ratio | 0x | 478.67x |
| P/B Ratio | 3.12x | 3.27x |
| EPS | ₹4.47 | ₹2.35 |
| Book Value | ₹508.64 | ₹308.43 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | ONESOURCE | ORCHPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 0.5% | -1.5% |
| EPS Growth (TTM YoY) | -95.3% | 0% |
| Qtr Sales Growth | -0.57% | 0% |
| Qtr Profit Growth | 104.92% | 270.21% |
Profitability & Leverage
| Metric | ONESOURCE | ORCHPHARMA |
|---|---|---|
| ROE | 0.36% | 3.3% |
| ROCE | 1.97% | 3.77% |
| Net Margin | -5.19% | 2.51% |
| Operating Margin | 10.09% | 7.2% |
| Debt to Equity | 0.21x | 0.13x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ONESOURCE | ORCHPHARMA |
|---|---|---|
| Promoter Holding | 30.48% | 69.84% |
| FII Holding | 19.19%▲ 1.69 pp | 0.81%▼ 0.06 pp |
| DII Holding | 23.38%▲ 2.77 pp | 20.75%▲ 0.5 pp |
| Public Holding | 26.94%▼ 4.47 pp | 8.61%▼ 0.44 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ONESOURCE SPECL PHARMA L and ORCHID PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.